<DOC>
	<DOCNO>NCT02923583</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety M834 Orencia ® follow administration single-dose healthy volunteer .</brief_summary>
	<brief_title>Assessment Pharmacokinetics ( PK ) Safety M834 Orencia ® , Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Male female 18 55 year age , inclusive ( ethnic origin ) . 2 . Healthy determine medical history , physical examination , vital sign , 12 lead electrocardiography ( ECG ) screening . 3 . Body mass index ( BMI ) 18 32 kg/m2 . 4 . Body weight 50.0 100.0 kg , inclusive . 5 . Has smoke 10 cigarette , 3 cigar , 3 pipes/day least 1 month prior screen willing comply smoking restriction confinement study center . 6 . Willing able comply requirement study . 7 . Willing able sign write informed consent . 1 . History and/or current presence clinically significant angioedema , clinically significant hypersensitivity , severe allergic reaction ( either spontaneous follow drug administration ) , also include know suspected clinically relevant drug hypersensitivity component study drug comparable drug , latex . 2 . History invasive systemic fungal infection ( e.g. , histoplasmosis , coccidioidomycosis ) severe opportunistic infection ; subject wellcontrolled mild recurrent chronic local fungal infection ( e.g. , tinea versicolor , onychomycosis , athlete 's foot ) may include discretion Investigator . 3 . A serious infection ( associate hospitalization and/or require intravenous antiinfectives ) within 6 month study drug administration significant infection require oral topical antiinfectives within 4 week study drug administration . 4 . Any minor infection within 2 week admission clinical unit Day 1 , opinion Investigator , may require systemic therapy otherwise impact safety participation study . 5 . Herpes zoster infection last year 1 herpes zoster infection his/her lifetime . 6 . Frequent chronic recurrent infection ( define &gt; 3 year require prescribe antibiotic treatment ; subject &gt; 3 viral upper respiratory infection may consider base Investigator discretion ) . 7 . Previous administration abatacept , belatacept , biosimilar candidate reference abatacept belatacept . 8 . Receipt another recombinant human monoclonal antibody within 6 month prior dose trial , within 5 halflives , within expect period pharmacodynamic effect ; whichever long . 9 . Intake study drug another trial within 3 month prior dose trial receive last dose investigational drug &gt; 3 month ago extend followup , plan dose investigational drug ( study ) course trial . 10 . History alcohol abuse past year , history regular consumption alcohol , unwillingness comply alcohol restriction outline . 11 . History drug abuse . 12 . Donation blood within 3 month blood product ( e.g. , platelet within 6 week , plasma within 7 day ) prior dose . 13 . Use prescribed nonprescribed medication , dietary supplement herbal medication 2 week prior dose . 14 . History current congestive heart failure . 15 . History current sign symptom demyelinate disease include optic neuritis and/or multiple sclerosis . 16 . History cancer include lymphoma , leukemia , skin cancer cervical carcinoma situ . 17 . History immunodeficiency ( include subject positive test human immunodeficiency virus [ HIV ] I II screen ) clinically significant immunological disorder , autoimmune disorder . Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , hematological , metabolic , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder judge investigator . 18 . Received live vaccine within 12 week prior clinic admission ( Day 1 ) plan receive live vaccine study ( include Day 71 ) . 19 . Pregnant breastfeed woman . 20 . Men woman childbearing potential unwilling practice adequate contraception study ( adequate contraceptive measure include use condom spermicide one follow highly effective method : stable use oral contraceptive prescription pharmaceutical contraceptive , intrauterine device ( IUD ) ; bilateral tubal ligation , vasectomy , additional barrier method [ e.g. , diaphragm , cap , sponge ] ) . Contraception required subject abstinent ( abstinence prefer usual lifestyle ; contraception use described subject stop abstinent ) , subject exclusive samesex relationship , postmenopausal female . Postmenopausal woman must amenorrheic least 12 month , confirm folliclestimulating hormone ( FSH ) level &gt; 40 IU/L screen order consider childbearing potential . Pregnancy test contraception require woman document hysterectomy , bilateral salpingectomy , bilateral oophorectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>